{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:51:49Z","timestamp":1770511909232,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.eplepsyres.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T07:47:46Z","timestamp":1478677666000},"page":"163-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration"],"prefix":"10.1016","volume":"128","author":[{"given":"Armel","family":"Stockis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L.","family":"Sargentini-Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2125.1997.00607.x","article-title":"The mechanism of the carbamazepine-valproate interaction in humans","volume":"44","author":"Bernus","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1528-1157.1998.tb01356.x","article-title":"Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?","volume":"39","author":"Besag","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0015","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/00007691-200112000-00017","article-title":"Methsuximide reduces valproic acid serum levels","volume":"23","author":"Besag","year":"2001","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0025","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF00606558","article-title":"Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy","volume":"09","author":"Eichelbaum","year":"1976","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy","volume":"30","author":"International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0045","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/jm030913e","article-title":"Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity","volume":"47","author":"Kenda","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0050","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0055","unstructured":"McDonough, B., Colson, A., Stockis, A., Johnson, M., Whitesides, J. (2015). Brivaracetam-induced elevation of carbamazepine-epoxide levels: a safety analysis, Abstract No: 1.224, American Epilepsy Society Annual Meeting. Available at: www.aesnet.org."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0060","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","article-title":"Estimation of the burden of active and life-time epilepsy: a meta-analytic approach","volume":"51","author":"Ngugi","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0065","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0070","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00007691-199812000-00012","article-title":"Carbamazepine-10,11-epoxide in therapeutic drug monitoring","volume":"20","author":"Potter","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males","volume":"66","author":"Rolan","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0085","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2006.02829.x","article-title":"The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males","volume":"63","author":"Sargentini-Maier","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/dmd.107.017129","article-title":"Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects","volume":"36","author":"Sargentini-Maier","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0095","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1177\/0091270011431457","article-title":"Brivaracetam disposition in renal impairment","volume":"52","author":"Sargentini-Maier","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0100","doi-asserted-by":"crossref","first-page":"g254","DOI":"10.1136\/bmj.g254","article-title":"Drug treatment of epilepsy in adults","volume":"348","author":"Schmidt","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0105","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcph.187","article-title":"Effect of brivaracetam (400mg\/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women","volume":"53","author":"Stockis","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0110","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/epi.12535","article-title":"Interaction between brivaracetam (100mg\/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study","volume":"55","author":"Stockis","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0115","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2133\/dmpk.DMPK-14-RG-010","article-title":"Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype","volume":"29","author":"Stockis","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eplepsyres.2015.03.003","article-title":"Brivaracetam and carbamazepine interaction in healthy subjects and in vitro","volume":"113","author":"Stockis","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0125","first-page":"185","article-title":"Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100mg tablets and 100mg intravenous bolus","volume":"55","author":"Stockis","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0130","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/dmd.115.069161","article-title":"Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis","volume":"44","author":"Stockis","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0135","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00007691-199612000-00006","article-title":"Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication","volume":"18","author":"Svinarov","year":"1996","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.410250215","article-title":"Carbamazepine and its epoxide: relation of plasma levels to toxicity and seizure control","volume":"25","author":"Theodore","year":"1989","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2016.11.001_bib0145","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/archneur.1990.00530080072013","article-title":"Carbamazepine-10,11-epoxide in epilepsy a pilot study","volume":"47","author":"Tomson","year":"1990","journal-title":"Arch. Neurol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116302832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116302832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:36:57Z","timestamp":1760276217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121116302832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":29,"alternative-id":["S0920121116302832"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.11.001","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}